Be Bio Announces New Preclinical Data Demonstrating its Novel Engineered B Cell Medicine (BCM), BE-1
BE-101 is Company’s Lead Program in Hemophilia B; IND Filing Anticipated in Mid-2024Be Bio Appoints Glenn Pierce, M.D., Ph.D., Hemophilia Physician-Researcher and Advocate, to its Scientific Advisory BoardPreclinical Study Findings Shared in Oral Presentation During 65th Annual Meeting of the American Society of Hem...